Title
Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder
Comparison of Umbilical Cord Blood vs Personalized Treatment for Improving Autistic Spectrum Disorder
Phase
Phase 1Lead Sponsor
Fundatia Bio-ForumStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Autistic Spectrum DisorderIntervention/Treatment
Intranasal oxytocin Autologous umbilical cord bloodStudy Participants
35The clinical study evaluates in an open-label, crossover design the comparative efficacy and safety of intranasal oxytocin and autologous umbilical cord blood for improving the functioning of children with autistic spectrum disorder
Children aged 3-7 years diagnosed with autistic spectrum disorder and who did not previously receive oxytocin or umbilical cord blood treatments, will be enrolled to receive both treatments in random order. Assessment of functioning impairment will be done with QCHAT/M-CHAT/CAST questionnaires initially, at 2 months, 6 months and 1 year after first treatments. Either oxytocin or cord blood will be administered initially and at visit 2, which will take place at 2 months. All children will receive both treatments. A total of 25-40 children are expected to enroll and complete the study.
daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
Intravenous administration of autologous umbilical cord blood
Inclusion Criteria: diagnosis of autistic spectrum disorder Exclusion Criteria: metabolic or genetic disorder (ex storage disease, Down, etc),